Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Nivolumab and salvage nivolumab plus ipilimumab for aRCC

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations

Cell-free utDNA may predict transurethral resection of bladder tumour pathology in non–muscle invasive bladder cancer

IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC

Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer

L'importance de choisir judicieusement en oncologie chirurgicale

Choosing Wisely in haemato oncology and medical oncology